Dividendaandelen
TIP
Re: Dividendaandelen
lop schreef: ↑20 maart 2021, 16:54Kan hier eigenlijk goed mee lachen waarom schrijven ze dit na dat aandeelkoersen al hoger noteren ?Mattia schreef: ↑20 maart 2021, 12:59 Een analyse van Sean Williams (www.fool.com)
Mar 20, 2021 at 6:05AM
AT&T: 6.9% yield
Like Philip Morris and IBM, AT&T's best days are now in the rearview mirror. But that doesn't mean Ma Bell doesn't have a few tricks up its sleeve to move the needle in the right direction.
For example, the rollout of 5G networks should be a significant positive for AT&T. It's been a decade since the last upgrade of wireless download speeds, which suggests that consumers and businesses will be jumping at the prospect of updating their wireless devices. Since AT&T generates its juiciest margins from wireless data, an increase in download speeds can only improve its operating margins.
AT&T also stands to benefit from its push into streaming. Despite a slow start to the launch of HBO Max in late May, AT&T's subscriber numbers have picked up significantly in recent months. This may have to do with subsidiary WarnerMedia releasing all of its movies in 2021 on HBO Max the same day they'll hit theaters. Offering exclusive content from the luxury of one's own couch could be the dangling carrot that puts HBO Max on the map.
With AT&T signaling numerous times that its dividend is safe, investors can comfortably count on this nearly 7% yield.
Wanneer een aandeel spotgoedkoop is zoals pm destijds of altria hoor je niks qua aanbevelingen .
De content van zo'n artikels is eigenlijk een grap .
Je begint nu ook artikels te vinden over WBA maar toen het 25% lager noteerde hoorde je niets![]()
Dat zijn dan de specialisten![]()
achter de feiten aanlopen
Ik heb reeds op 3 december dit aandeel op mijn scherm zien verschijnen maar je hebt gelijk, het was via een betalend abonnement .....dat belet niet dat ik dit gratis artikel misken, de koers kan er maar wel bij varen ....
Re: Dividendaandelen
Hier kan je de volledige historiek zien : https://www.gsk.com/en-gb/investors/sha ... lator-gbp/
Er is in 2009 geen daling geweest.
En er is in 2016 een extra dividend van 20p uitgekeerd. Dat was dus eerder een uitzonderlijke verhoging, geen “knip”
Er is wel aangekondigd dat het dividend wellicht zal dalen vanaf ‘22 na de opsplitsing.
Re: Dividendaandelen
ontbreken dan cijfers nochtans vind ik bij meerdere sites hetzelfde , staan maar 2 kwartaaluitkeringen onder 2008 zouNipo schreef: ↑20 maart 2021, 23:15
Hier kan je de volledige historiek zien : https://www.gsk.com/en-gb/investors/sha ... lator-gbp/
Er is in 2009 geen daling geweest.
En er is in 2016 een extra dividend van 20p uitgekeerd. Dat was dus eerder een uitzonderlijke verhoging, geen “knip”
Er is wel aangekondigd dat het dividend wellicht zal dalen vanaf ‘22 na de opsplitsing.
niet de eerste keer zijn dat er een fout instaat.
Het dividend zal in elk geval dalen want hun uitbetaling zal boven de 90% uitkomen dit jaar .
Zal het aandeel aantrekkelijker maken als ze het dividend met de helft doen zakken
Nu daalt de omzet elk jaar
05/02/2020 Final GBX 23 31/12/2018 31/12/2019 20/02/2020 21/02/2020 09/04/2020 80
30/10/2019 1 GBX 19 31/12/2018 31/12/2019 14/11/2019 15/11/2019 09/01/2020 0
24/07/2019 1 GBX 19 31/12/2018 31/12/2019 08/08/2019 09/08/2019 10/10/2019 0
01/05/2019 1 GBX 19 31/12/2018 31/12/2019 16/05/2019 17/05/2019 11/07/2019 0
06/02/2019 Final GBX 23 31/12/2017 31/12/2018 21/02/2019 22/02/2019 11/04/2019 80
31/10/2018 1 GBX 19 31/12/2017 31/12/2018 15/11/2018 16/11/2018 10/01/2019 0
25/07/2018 1 GBX 19 31/12/2017 31/12/2018 09/08/2018 10/08/2018 11/10/2018 0
25/04/2018 1 GBX 19 31/12/2017 31/12/2018 10/05/2018 11/05/2018 12/07/2018 0
07/02/2018 Final GBX 23 31/12/2016 31/12/2017 22/02/2018 23/02/2018 12/04/2018 80
25/10/2017 1 GBX 19 31/12/2016 31/12/2017 09/11/2017 10/11/2017 11/01/2018 0
26/07/2017 1 GBX 19 31/12/2016 31/12/2017 10/08/2017 11/08/2017 12/10/2017 0
26/04/2017 1 GBX 19 31/12/2016 31/12/2017 11/05/2017 12/05/2017 13/07/2017 0
08/02/2017 Final GBX 23 31/12/2015 31/12/2016 23/02/2017 24/02/2017 13/04/2017 80
26/10/2016 1 GBX 19 31/12/2015 31/12/2016 03/11/2016 04/11/2016 12/01/2017 0
27/07/2016 1 GBX 19 31/12/2015 31/12/2016 11/08/2016 12/08/2016 13/10/2016 0
27/04/2016 1 GBX 19 31/12/2015 31/12/2016 12/05/2016 13/05/2016 14/07/2016 0
03/02/2016 Special GBX 20 31/12/2014 31/12/2015 18/02/2016 19/02/2016 14/04/2016 0
03/02/2016 Final GBX 23 31/12/2014 31/12/2015 18/02/2016 19/02/2016 14/04/2016 100
19/10/2015 1 GBX 19 31/12/2014 31/12/2015 12/11/2015 13/11/2015 14/01/2016 0
29/07/2015 1 GBX 19 31/12/2014 31/12/2015 13/08/2015 14/08/2015 01/10/2015 0
06/05/2015 1 GBX 19 31/12/2014 31/12/2015 14/05/2015 15/05/2015 09/07/2015 0
04/02/2015 Final GBX 23 31/12/2013 31/12/2014 19/02/2015 20/02/2015 09/04/2015 80
22/10/2014 1 GBX 19 31/12/2013 31/12/2014 06/11/2014 07/11/2014 08/01/2015 0
24/07/2014 1 GBX 19 31/12/2013 31/12/2014 06/08/2014 08/08/2014 02/10/2014 0
30/04/2014 1 GBX 19 31/12/2013 31/12/2014 14/05/2014 16/05/2014 10/07/2014 0
05/02/2014 Final GBX 23 31/12/2012 31/12/2013 19/02/2014 21/02/2014 10/04/2014 78
23/10/2013 1 GBX 19 31/12/2012 31/12/2013 13/11/2013 15/11/2013 09/01/2014 0
24/07/2013 1 GBX 18 31/12/2012 31/12/2013 07/08/2013 09/08/2013 03/10/2013 0
24/04/2013 1 GBX 18 31/12/2012 31/12/2013 08/05/2013 10/05/2013 11/07/2013 0
06/02/2013 Final GBX 22 31/12/2011 31/12/2012 20/02/2013 22/02/2013 11/04/2013 74
31/10/2012 1 GBX 18 31/12/2011 31/12/2012 14/11/2012 16/11/2012 03/01/2013 0
25/07/2012 1 GBX 17 31/12/2011 31/12/2012 08/08/2012 10/08/2012 04/10/2012 0
25/04/2012 1 GBX 17 31/12/2011 31/12/2012 09/05/2012 11/05/2012 05/07/2012 0
07/02/2012 Special GBX 5 31/12/2010 31/12/2011 15/02/2012 17/02/2012 12/04/2012 0
07/02/2012 Final GBX 21 31/12/2010 31/12/2011 15/02/2012 17/02/2012 12/04/2012 75
26/10/2011 Interim GBX 17 31/12/2010 31/12/2011 02/11/2011 04/11/2011 05/01/2012 0
26/07/2011 Interim GBX 16 31/12/2010 31/12/2011 03/08/2011 05/08/2011 06/10/2011 0
27/04/2011 Interim GBX 16 31/12/2010 31/12/2011 04/05/2011 06/05/2011 07/07/2011 0
03/02/2011 Final GBX 19 31/12/2009 31/12/2010 09/02/2011 11/02/2011 07/04/2011 65
21/10/2010 Interim GBX 16 31/12/2009 31/12/2010 27/10/2010 29/10/2010 06/01/2011 0
21/07/2010 Interim GBX 15 31/12/2009 31/12/2010 28/07/2010 30/07/2010 07/10/2010 0
28/04/2010 Interim GBX 15 31/12/2009 31/12/2010 05/05/2010 07/05/2010 08/07/2010 0
04/02/2010 Final GBX 18 31/12/2008 31/12/2009 10/02/2010 12/02/2010 08/04/2010 61
29/10/2009 1 GBX 15 31/12/2008 31/12/2009 04/11/2009 06/09/2009 07/01/2010 0
30/07/2009 1 GBX 14 31/12/2008 31/12/2009 31/07/2009 31/07/2009 08/10/2009 28
22/04/2009 1 GBX 14 31/12/2008 31/12/2009 29/04/2009 01/05/2009 09/07/2009 0
05/02/2009 Final GBX 17 31/12/2007 31/12/2008 11/02/2009 13/02/2009 09/04/2009 57
22/10/2008 1 GBX 14 31/12/2007 31/12/2008 29/10/2008 31/10/2008 09/01/2008 0
07/02/2008 Final GBX 13 31/12/2006 31/12/2007 13/02/2008 15/02/2008 10/04/2008 53
25/07/2007 1 GBX 12 31/12/2006 31/12/2007 01/08/2007 03/08/2007 11/10/2007 0
24/04/2007 1 GBX 12 31/12/2006 31/12/2007 02/05/2007 04/05/2007 12/07/2007 0
08/02/2007 1 GBX 14 31/12/2005 31/12/2006 14/02/2006 16/02/2006 12/04/2007 0
08/02/2007 Final GBX 0 31/12/2005 31/12/2006 01/01/1970 01/01/1970 01/01/1970 48
26/10/2006 1 GBX 12 31/12/2005 31/12/2006 01/11/2006 03/11/2006 04/01/2007 0
26/07/2006 1 GBX 11 31/12/2005 31/12/2006 02/08/2006 04/08/2006 05/10/2006 0
27/04/2006 1 GBX 11 31/12/2005 31/12/2006 10/05/2006 12/05/2006 06/07/2006 0
08/02/2006 Final GBX 14 31/12/2004 31/12/2005 15/02/2006 17/02/2006 06/04/2006 44
27/10/2005 1 GBX 10 31/12/2004 31/12/2005 02/11/2005 04/11/2005 05/01/2006 0
29/07/2005 1 GBX 10 31/12/2004 31/12/2005 03/08/2005 05/08/2005 06/10/2005 0
28/04/2005 1 GBX 10 31/12/2004 31/12/2005 11/05/2005 13/05/2005 07/07/2005 0
10/02/2005 Final GBX 12 31/12/2003 31/12/2004 16/02/2005 18/02/2005 07/04/2005 42
28/10/2004 1 GBX 10 31/12/2003 31/12/2004 03/11/2004 05/11/2004 06/01/2005 0
27/07/2004 1 GBX 10 31/12/2003 31/12/2004 12/05/2004 14/05/2004 01/07/2004 0
27/07/2004 1 GBX 10 31/12/2003 31/12/2004 04/08/2004 06/08/2004 30/09/2004 0
12/02/2004 Final GBX 14 31/12/2002 31/12/2003 18/02/2004 20/02/2004 15/04/2004 41
11/02/2004 1 GBX 9 31/12/2002 31/12/2003 29/10/2003 31/10/2003 06/01/2004 0
23/07/2003 1 GBX 9 31/12/2002 31/12/2003 30/07/2003 01/08/2003 02/10/2003 0
30/04/2003 1 GBX 9 31/12/2002 31/12/2003 07/05/2003 09/05/2003 03/07/2003 0
12/02/2003 Final GBX 13 31/12/2001 31/12/2002 19/02/2003 21/02/2003 17/04/2003 40
23/10/2002 1 GBX 9 30/03/2002 30/09/2002 30/10/2002 01/11/2002 03/01/2003 0
24/07/2002 1 GBX 9 30/12/2001 30/06/2002 31/07/2002 02/08/2002 03/10/2002 0
25/04/2002 1 GBX 9 01/10/2001 31/03/2002 01/05/2002 03/05/2002 04/07/2002 0
14/02/2002 Final GBX 12 31/12/2000 31/12/2001 20/02/2002 22/02/2002 18/04/2002 39
23/10/2001 1 GBX 9 30/09/2000 30/09/2001 31/10/2001 02/11/2001 03/01/2002 0
24/07/2001 1 GBX 9 30/06/2000 30/06/2001 01/08/2001 03/08/2001 04/10/2001 0
24/04/2001 1 GBX 9 31/03/2000 31/03/2001 02/05/2001 04/05/2001 05/07/2001 0
13/12/2000 Final GBX 23 31/12/1999 31/12/2000 18/12/2000 22/12/2000 17/04/2001 38
27/07/2000 Interim GBX 15 30/12/1999 30/06/2000 07/08/2000 11/08/2000 16/10/2000 0
16/02/2000 Final GBX 22 31/12/1998 31/12/1999 28/02/2000 03/03/2000 25/05/2000 37
29/07/1999 Interim GBX 15 30/12/1998 30/06/1999 09/08/1999 13/08/1999 01/10/1999 0
18/02/1999 Final GBX 21 31/12/1997 31/12/1998 01/03/1999 05/03/1999 20/05/1999 36
Re: Dividendaandelen
Beste buy en forget aandelen momenteel bedoeld om zo weinig mogelijk te handelen
ticker risico dividend gr , dividend 10y gemiddeld , dividend , groei , total return
1) GD A 28 jaar 2,3% 2,7% 6 % 8,7%
2) CL A 56 2,3% 2,4% 5% 7,4%
3) HRL A 55 1,7% 2,0% 5% 7%
4) AMGN B 10 2,2% 2,9% 9% 11,9%
5) CMCSA B 13 1,7% 1,8% 10% 11,8%
6) HD B 12 2,1% 2,3% 9% 11,3%
7) ORCL B 12 1.3% 1,9% 8% 9,9%
CSCO B 11 2,8% 3,0% 6% 9,0%
9) AMT B 9 1,7% 2,2% 6% 8,2%
10) AOS B 27 1,3% 1,5% 6% 7,5%
ticker risico dividend gr , dividend 10y gemiddeld , dividend , groei , total return
1) GD A 28 jaar 2,3% 2,7% 6 % 8,7%
2) CL A 56 2,3% 2,4% 5% 7,4%
3) HRL A 55 1,7% 2,0% 5% 7%
4) AMGN B 10 2,2% 2,9% 9% 11,9%
5) CMCSA B 13 1,7% 1,8% 10% 11,8%
6) HD B 12 2,1% 2,3% 9% 11,3%
7) ORCL B 12 1.3% 1,9% 8% 9,9%

9) AMT B 9 1,7% 2,2% 6% 8,2%
10) AOS B 27 1,3% 1,5% 6% 7,5%
Re: Dividendaandelen
Jammer genoeg plakt hij alle cijfers tegen elkaar
Je zal moeten beter kijken

Je zal moeten beter kijken
Re: Dividendaandelen
http://www.aosmith.com
AOS produceert boilers en water- en luchtzuiveringsinstallaties voor zowel bedrijven als particulieren in meer dan 60 landen over de hele wereld.
De producten worden verdeeld via onafhankelijke groothandels voor loodgieters, maar ook via retail-kanalen zoals bouwmarkten.
Hoewel het overgrote deel van de verkopen nog steeds plaatsvindt in de VS (een netwerk van 1.300 licentiehouders), zorgt de snelle groei van de internationale verkoop (vooral in China) dat AOS geografisch snel diversifieert.
Het hoofdkantoor staat in Milwaukee en er zijn wereldwijd circa 16.000 mensen in dienst.
De omzet lag voor AOS in 2020 ongeveer 3% lager dan in 2019 wat voornamelijk door de gevolgen van de wereldwijde lockdown kon worden verklaard.
Voor 2021 blijft de onderneming positief, al blijft er natuurlijk nog wel enige onzekerheid bestaan over de duur en de lange termijn gevolgen van de pandemie.
In de veronderstelling dat de omstandigheden in 2021 vergelijkbaar blijven met de afgelopen maanden, gaat AOS voor 2021 uit van een wpa van $2,40-$2,50.
Gezien de sterke vooruitzichten de komende jaren, blijft het aandeel zeer koopwaardig voor lange termijn beleggers.
AOS produceert boilers en water- en luchtzuiveringsinstallaties voor zowel bedrijven als particulieren in meer dan 60 landen over de hele wereld.
De producten worden verdeeld via onafhankelijke groothandels voor loodgieters, maar ook via retail-kanalen zoals bouwmarkten.
Hoewel het overgrote deel van de verkopen nog steeds plaatsvindt in de VS (een netwerk van 1.300 licentiehouders), zorgt de snelle groei van de internationale verkoop (vooral in China) dat AOS geografisch snel diversifieert.
Het hoofdkantoor staat in Milwaukee en er zijn wereldwijd circa 16.000 mensen in dienst.
De omzet lag voor AOS in 2020 ongeveer 3% lager dan in 2019 wat voornamelijk door de gevolgen van de wereldwijde lockdown kon worden verklaard.
Voor 2021 blijft de onderneming positief, al blijft er natuurlijk nog wel enige onzekerheid bestaan over de duur en de lange termijn gevolgen van de pandemie.
In de veronderstelling dat de omstandigheden in 2021 vergelijkbaar blijven met de afgelopen maanden, gaat AOS voor 2021 uit van een wpa van $2,40-$2,50.
Gezien de sterke vooruitzichten de komende jaren, blijft het aandeel zeer koopwaardig voor lange termijn beleggers.
Re: Dividendaandelen
Kan de verslagen niet posten is 55 bladzijden lang , maar je weet op wat je kan zoeken
Re: Dividendaandelen
Dat was een analyse van Eveline, cijfers hieronder:
A.O. Smith Corporation Common
Ticker AOS
Beurs NYSE
ISIN US8318652091
Website http://www.aosmith.com
Sector Industrials
Industrie Industriële goederen
Slotkoers laatste beursdag (19-03-2021) $ 67,48
Slotkoers laatste maand (26-02-2021) $ 59,37
Winst per aandeel (laatste 4 kwartalen) $ 2,12
Dividend (laatste kwartaal x 4) $ 1,04
Dividendrendement 1,62 %
Payout ratio (laatste 4 kwartalen) 46 %
Kooplimiet $ 65,83
Groeipercentage winst per aandeel afgelopen 3 jaar 7,64%
Groeipercentage dividend afgelopen 5 jaar 20,86%
Koers/winst verhouding (forwarding) 25,58
Koers/winst verhouding gemiddelde afgelopen 5 jaar 25,77
Boekwaarde per aandeel laatste kwartaal $ 11,44
Verhouding schuld/bezittingen laatste kwartaal 0,08
Hoogste Theoretische Koers $ 100,72
Laagste Theoretische Koers $ 65,83
Hoogste koers in 52 weken $ 65,83
Laagste koers in 52 weken $ 33,81
Hoogste koers in 5 jaar $ 68,39
Laagste koers in 5 jaar $ 33,81
Ik zie dat er nogal wat van jouw aandelen in haar portfolio zitten en dus heb ik ook nogal wat analyses beschikbaar.
Toch bedankt.
Re: Dividendaandelen
Deze die ik nu poste zijn de veiligste , buy en hold
Krijg ze ook voor veiligste inkomsten , pensioen
En de best gewaardeerde volgens veiligheid
En databank waar ook de risicovoller aandelen inzitten
Zou moeten overlap inzitten met andere analisten toch voor deze die ik nu poste
De best gewaardeerde heb ik nog niet ondervonden dat andere analisten dit zo berekenen .
Heeft me al veel opgebracht in het verleden ,
En is eindelijk het paradepaardje omdat het uniek is .
Andere analisten bevelen deze maar aan als de koers al terug in stijgende lijn zit .
Aan de andere kant heb ik al enkele keren ondervonden dat ze te vroeg zijn in hun aanbevelingen , maar waarvan ik dan achterna denk had ik maar meer gekocht toen
Als voorbeeld
TGT heeft ook nog 10% lager gegaan toen zij het aanbevolen maar is intussen met 200% gestegen
Zal niemand exact kunnen timen
Krijg ze ook voor veiligste inkomsten , pensioen
En de best gewaardeerde volgens veiligheid
En databank waar ook de risicovoller aandelen inzitten
Zou moeten overlap inzitten met andere analisten toch voor deze die ik nu poste
De best gewaardeerde heb ik nog niet ondervonden dat andere analisten dit zo berekenen .
Heeft me al veel opgebracht in het verleden ,
En is eindelijk het paradepaardje omdat het uniek is .
Andere analisten bevelen deze maar aan als de koers al terug in stijgende lijn zit .
Aan de andere kant heb ik al enkele keren ondervonden dat ze te vroeg zijn in hun aanbevelingen , maar waarvan ik dan achterna denk had ik maar meer gekocht toen

Als voorbeeld
TGT heeft ook nog 10% lager gegaan toen zij het aanbevolen maar is intussen met 200% gestegen
Zal niemand exact kunnen timen
Re: Dividendaandelen
GuruFocus.com: analyse by Nathan Parsh, Tue, March 23, 2021, 5:41 PM
Pfizer
Pfizer Inc. (NYSE:PFE) has undergone a significant transformation recently.
Pfizer formed a joint venture with GlaxoSmithKline plc (NYSE:GSK) that includes the company's over-the-counter business.
Pfizer owns approximately a third of the joint venture.
The company also spun off its off patent, branded and generic medicines business, which was then merged with Mylan to form Viatris (NASDAQ:VTRS).
Top products include Eliquis, which the company developed with Bristol-Myers, Ibrance, used to treat breast cancer, and Prevnar 13, used to prevent infection from certain bacteria.
The company has annual revenues of almost $42 billion.
Shareholders received a 2.6% dividend increase for the March 5 payment.
As a result, Pfizer has now increased its dividend for 11 consecutive years.
Following a major acquisition in 2009, the company cut its dividend two consecutive years.
However, the dividend has a compound annual growth rate of almost 6% since 2011.
In total, Pfizer has raised its dividend in 52 out of the past 54 years.
The company's annualized dividend is $1.56.
This results in a projected payout ratio of 47% for 2021, just below the 10-year average payout ratio of 48%.
Like Merck, Pfizer's payout ratio has been rather consistent over the last decade, usually in a range of 40% to 50%.
For context, the stock has averaged a yield of 3.7% since 2011.
Pfizer is expected to earn $3.31 in 2021.
The stock closed the most recent trading session at $36.
Using estimates for the current year, shaves have a forward price-earnings ratio of 10.9.
The company has an average multiple of almost 21 times earnings since 2012.
I have stated previously that I have a target price-earnings range of 14 to 16 for the stock, which would have Pfizer trading much more in line with peers.
Valuation could be a substantial tailwind to shareholder returns were the stock to trade with my target.
Shares have a GF Value of $38.68, which results in a price-to-GF Value of 0.93.
This earns Pfizer a rating of fairly valued, but shareholders would see a 7.4% return if the stock were to reach its GF Value. Combined with the dividend and total returns could be in the low double digits.
Pfizer has made changes to its business model recently as it is now more focused on the faster-growing pharmaceutical segment as opposed to generic medicines and consumer products.
Even with two dividend cuts, Pfizer's long-term dividend track record is impressive and the current yield is robust.
The payout ratio is very reasonable and in line with the historical averages.
Given its low valuation and high yield, Pfizer could be a good name to own at the current price.
Pfizer
Pfizer Inc. (NYSE:PFE) has undergone a significant transformation recently.
Pfizer formed a joint venture with GlaxoSmithKline plc (NYSE:GSK) that includes the company's over-the-counter business.
Pfizer owns approximately a third of the joint venture.
The company also spun off its off patent, branded and generic medicines business, which was then merged with Mylan to form Viatris (NASDAQ:VTRS).
Top products include Eliquis, which the company developed with Bristol-Myers, Ibrance, used to treat breast cancer, and Prevnar 13, used to prevent infection from certain bacteria.
The company has annual revenues of almost $42 billion.
Shareholders received a 2.6% dividend increase for the March 5 payment.
As a result, Pfizer has now increased its dividend for 11 consecutive years.
Following a major acquisition in 2009, the company cut its dividend two consecutive years.
However, the dividend has a compound annual growth rate of almost 6% since 2011.
In total, Pfizer has raised its dividend in 52 out of the past 54 years.
The company's annualized dividend is $1.56.
This results in a projected payout ratio of 47% for 2021, just below the 10-year average payout ratio of 48%.
Like Merck, Pfizer's payout ratio has been rather consistent over the last decade, usually in a range of 40% to 50%.
For context, the stock has averaged a yield of 3.7% since 2011.
Pfizer is expected to earn $3.31 in 2021.
The stock closed the most recent trading session at $36.
Using estimates for the current year, shaves have a forward price-earnings ratio of 10.9.
The company has an average multiple of almost 21 times earnings since 2012.
I have stated previously that I have a target price-earnings range of 14 to 16 for the stock, which would have Pfizer trading much more in line with peers.
Valuation could be a substantial tailwind to shareholder returns were the stock to trade with my target.
Shares have a GF Value of $38.68, which results in a price-to-GF Value of 0.93.
This earns Pfizer a rating of fairly valued, but shareholders would see a 7.4% return if the stock were to reach its GF Value. Combined with the dividend and total returns could be in the low double digits.
Pfizer has made changes to its business model recently as it is now more focused on the faster-growing pharmaceutical segment as opposed to generic medicines and consumer products.
Even with two dividend cuts, Pfizer's long-term dividend track record is impressive and the current yield is robust.
The payout ratio is very reasonable and in line with the historical averages.
Given its low valuation and high yield, Pfizer could be a good name to own at the current price.
Re: Dividendaandelen
95% payout in 2021 verwachting om te dalen naar 82% tegen 2026Mattia schreef: ↑23 maart 2021, 19:33 Vandaag Broadmark aangekocht.
https://finance.yahoo.com/quote/BRMK?p=BRMK
P/E ratio 11,7 verwachting is dat dit daalt naar 10 tegen 2026
verwachte groei 3%
dividend= 8,2%
valuatie tegenwind =3,9%
Total return =6,1%
Risico score =F
Niet echt schitterend op zijn minst gezegd
Re: Dividendaandelen
www.fool.com: Analyse van Chuck Saletta;
http://www.broadmark.com
A hard-money lender that owes no debt of its own:
One of the big challenges associated with investing in companies that lend out money is that they themselves tend to have debts of their own to pay.
Debts bring with them obligations, including the obligation to make sufficient and on time payments.
In addition, they also have additional strings attached in the form of covenants that limit how the borrower can act.
That means that when a lender itself owes money, there's a good chance there's only so much it can do to enable flexibility with its borrowers when the lending market dries up.
It's also why Broadmark Realty Capital (NYSE:BRMK) is such a compelling potential investment.
A hard-money, construction-focused lender, Broadmark Realty has absolutely no debt of its own on its balance sheet.
That gives it incredible flexibility when times get tight, since it doesn't have to answer to lenders of its own.
Of course, construction is an economically sensitive business, and when times get tight, progress can stall.
That could leave Broadmark in a situation where it may find itself with unfinished construction projects and limited cash flows on its hands.
The way it manages that is by insisting on no more than a 65% loan to value ratio on the properties it lends on, which gives it a buffer if it does have to take possession of a property.
Despite those precautions, the market sees risk in its business, which is why its shares offer a yield of around 7.9%.
Its dividend gets paid monthly, and as it is structured as a REIT, it has to pay out at least 90% of its earnings in the form of a dividend.
That provides reason to believe that as long as its business remains profitable, its investors should expect to receive a dividend.
http://www.broadmark.com
A hard-money lender that owes no debt of its own:
One of the big challenges associated with investing in companies that lend out money is that they themselves tend to have debts of their own to pay.
Debts bring with them obligations, including the obligation to make sufficient and on time payments.
In addition, they also have additional strings attached in the form of covenants that limit how the borrower can act.
That means that when a lender itself owes money, there's a good chance there's only so much it can do to enable flexibility with its borrowers when the lending market dries up.
It's also why Broadmark Realty Capital (NYSE:BRMK) is such a compelling potential investment.
A hard-money, construction-focused lender, Broadmark Realty has absolutely no debt of its own on its balance sheet.
That gives it incredible flexibility when times get tight, since it doesn't have to answer to lenders of its own.
Of course, construction is an economically sensitive business, and when times get tight, progress can stall.
That could leave Broadmark in a situation where it may find itself with unfinished construction projects and limited cash flows on its hands.
The way it manages that is by insisting on no more than a 65% loan to value ratio on the properties it lends on, which gives it a buffer if it does have to take possession of a property.
Despite those precautions, the market sees risk in its business, which is why its shares offer a yield of around 7.9%.
Its dividend gets paid monthly, and as it is structured as a REIT, it has to pay out at least 90% of its earnings in the form of a dividend.
That provides reason to believe that as long as its business remains profitable, its investors should expect to receive a dividend.